Claret Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.11M | Buy |
288,881
+2,911
| +1% | +$77.5K | 0.97% | 30 |
|
|
2025
Q4 | $7.12M | Buy |
285,970
+1,993
| +0.7% | +$50.3K | 0.83% | 31 |
|
|
2025
Q3 | $7.24M | Sell |
283,977
-24,545
| -8% | -$606K | 0.86% | 30 |
|
|
2025
Q2 | $7.48M | Buy |
308,522
+15,729
| +5% | +$367K | 0.97% | 27 |
|
|
2025
Q1 | $7.42M | Sell |
292,793
-3,099
| -1% | -$81.1K | 1.07% | 24 |
|
|
2024
Q4 | $7.85M | Buy |
295,892
+175,273
| +145% | +$4.75M | 1.24% | 22 |
|
|
2024
Q3 | $3.49M | Sell |
120,619
-889
| -0.7% | -$25.9K | 0.57% | 35 |
|
|
2024
Q2 | $3.4M | Sell |
121,508
-1,745
| -1% | -$48K | 0.6% | 35 |
|
|
2024
Q1 | $3.42M | Buy |
123,253
+29,353
| +31% | +$815K | 0.57% | 37 |
|
|
2023
Q4 | $2.7M | Buy |
93,900
+85,911
| +1,075% | +$2.6M | 0.48% | 39 |
|
|
2023
Q3 | $265K | Buy |
7,989
+524
| +7% | +$18.5K | 0.05% | 113 |
|
|
2023
Q2 | $274K | Buy |
7,465
+187
| +3% | +$7.28K | 0.05% | 119 |
|
|
2023
Q1 | $297K | Buy |
7,278
+50
| +0.7% | +$2.16K | 0.06% | 110 |
|
|
2022
Q4 | $370K | Buy |
7,228
+209
| +3% | +$10K | 0.08% | 105 |
|
|
2022
Q3 | $307K | Buy |
7,019
+550
| +9% | +$26.7K | 0.07% | 108 |
|
|
2022
Q2 | $339K | Sell |
6,469
-73
| -1% | -$3.72K | 0.07% | 108 |
|
|
2022
Q1 | $339K | Buy |
6,542
+329
| +5% | +$17.1K | 0.07% | 111 |
|
|
2021
Q4 | $367K | Sell |
6,213
-205
| -3% | -$10.2K | 0.07% | 116 |
|
|
2021
Q3 | $276K | Sell |
6,418
-3,637
| -36% | -$161K | 0.05% | 137 |
|
|
2021
Q2 | $394K | Buy |
10,055
+35
| +0.3% | +$1.36K | 0.06% | 125 |
|
|
2021
Q1 | $363K | Sell |
10,020
-748
| -7% | -$26.6K | 0.07% | 128 |
|
|
2020
Q4 | $396K | Sell |
10,768
-45,530
| -81% | -$1.67M | 0.08% | 126 |
|
|
2020
Q3 | $1.96M | Sell |
56,298
-527
| -0.9% | -$18.5K | 0.44% | 47 |
|
|
2020
Q2 | $1.76M | Buy |
56,825
+4,052
| +8% | +$138K | 0.42% | 49 |
|
|
2020
Q1 | $1.63M | Buy |
52,773
+10,888
| +26% | +$371K | 0.46% | 48 |
|
|
2019
Q4 | $1.56M | Sell |
41,885
-739
| -2% | -$26.3K | 0.3% | 61 |
|
|
2019
Q3 | $1.45M | Sell |
42,624
-143
| -0.3% | -$5.2K | 0.3% | 67 |
|
|
2019
Q2 | $1.76M | Sell |
42,767
-98
| -0.2% | -$3.89K | 0.36% | 60 |
|
|
2019
Q1 | $1.73M | Sell |
42,865
-448
| -1% | -$17.9K | 0.34% | 60 |
|
|
2018
Q4 | $1.79M | Sell |
43,313
-1,067
| -2% | -$44.3K | 0.4% | 61 |
|
|
2018
Q3 | $1.86M | Buy |
44,380
+1,366
| +3% | +$52.6K | 0.36% | 63 |
|
|
2018
Q2 | $1.48M | Sell |
43,014
-1,071
| -2% | -$36.6K | 0.3% | 67 |
|
|
2018
Q1 | $1.48M | Sell |
44,085
-14
| -0% | -$481 | 0.34% | 63 |
|
|
2017
Q4 | $1.51M | Buy |
+44,099
| New | +$1.5M | 0.33% | 64 |
|
Other funds holding PFE
VCM
VPM
Claret Asset Management's PFE Position: Q1 2026 in Review
Claret Asset Management increased its Pfizer (PFE) stake by 1% in Q1 2026, buying an estimated $77.5K and bringing the position to 288,881 shares worth $8.11M. The position accounts for 0.97% of the portfolio, ranked #30.
Claret Asset Management first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Claret Asset Management held 288,881 shares of Pfizer worth $8.11M as of Q1 2026.
- Claret Asset Management bought 2,911 Pfizer shares in Q1 2026, an estimated $77.5K.
- Pfizer made up 0.97% of Claret Asset Management's portfolio in Q1 2026, its #30 holding.
- Claret Asset Management first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Claret Asset Management's 13F filing for Q1 2026, filed 11 May 2026.